ARIAD PHARMACEUTICALS INC | 12,598 Euro | -0,490 -3,74 % | |
| WKN: 895301 ISIN: US04033A1007 Ticker-Symbol: APS | Frankfurt | 17.05.13 | 09:02 Uhr |
Branche PharmaAktienmarkt NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 16.05. | Ariad Pharmaceuticals Falling Today on Above-Average Volume | 4 | SmarTrend | |
| 16.05. | Shares of Ariad Pharmaceuticals Under Pressure, Down 6.3% | 5 | SmarTrend | |
| 15.05. | ARIAD Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) | 11 | Seeking Alpha | |
| 08.05. | Ariad Posts Wider Y/Y Loss | 13 | Zacks | |
| 08.05. | Does Ariad's Leukemia Drug Have Hidden Potential? | 18 | Motley Fool | |
| 07.05. | Ariad Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript | 2 | Seeking Alpha | |
| 07.05. | Ariad beats estimates with Q1 sales of Iclusig | 7 | bizjournals | |
| 07.05. | Ariad reports $6.4M in 1Q sales of leukemia pill | 6 | Yahoo-USA | |
| 07.05. | Ariad Pharmaceuticals Makes a Move: Up 6.4% | 2 | SmarTrend | |
| 07.05. | ARIAD PHARMACEUTICALS INC - 8-K, Current Report | 2 | SEC Filings | |
| 02.05. | Possible Bullish Inside Day Candle Pattern Detected for Ariad Pharmaceuticals | 9 | SmarTrend | |
| 24.04. | Bearish Moving Average Cross by Ariad Pharmaceuticals | 5 | SmarTrend | |
| 23.04. | MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCall's Microscope | 114 | PR Newswire | |
| LONDON, April 23, 2013 /PRNewswire/ --
Following the expiration of patents on several blockbuster drugs, big pharma companies have been looking to boost their product pipeline. While in-house research... Mehr lesen zu: MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCall's Microscope | ||||
| 12.04. | Ariad Presents Data on AP26113 | 23 | Zacks | |
| 10.04. | More Data on Ariad's Iclusig | 11 | Zacks | |
| 09.04. | Ariad Pharmaceuticals Bullish Moving Average Crossover Alert | 7 | SmarTrend | |
| 09.04. | Ariad Pharma Presents Preclinical Data On Ponatinib At AACR Annual Meeting | 73 | AFX News | |
| WASHINGTON (dpa-AFX) - Ariad Pharmaceuticals Inc. (ARIA) Tuesday announced
the presentation of preclinical data on gastrointestinal stromal tumors or GIST
compound ponatinib or Iclusig,... Mehr lesen zu: Ariad Pharma Presents Preclinical Data On Ponatinib At AACR Annual Meeting | ||||
| 09.04. | ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors | 7 | Benzinga.com | |
| 08.04. | ARIAD's leukemia drug Iclusig may be used in other cancer treatments | 2 | bizjournals | |
| 08.04. | ARIAD Pharmaceuticals Presents Preclinical Data On Ponatinib | 40 | AFX News | |
| WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals Inc. (ARIA) announced that it
presented preclinical data on ponatinib or Iclusig, at the American Association
for Cancer Research or AACR Annual... Mehr lesen zu: ARIAD Pharmaceuticals Presents Preclinical Data On Ponatinib | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| VERTEX PHARMACEUTICALS | 61,72 | +3,50 % | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report |
| ALEXION PHARMACEUTICALS | 80,22 | +2,89 % | Alexion geht durch die Decke! |
| SPECTRUM PHARMACEUTICALS | 6,22 | -0,02 % | Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma |
| INCYTE | 18,058 | +1,50 % | Incyte's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript) |
| GILEAD SCIENCES | 43,30 | +2,44 % | Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) |
